

our work

BioMS Medical
annual report
2008



A key moment for BioMS may lead to more moments for MS patients.

BioMS is a Canadian biotechnology company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of multiple sclerosis (MS). Their lead drug, dirucotide, is a synthetic peptide intravenously injected twice a year. In a Phase II trial, dirucotide safely delayed median time to disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.

BioMS has been working with Equicom since 2001 and is now reaching the finish line of a long journey. The 2008 annual report is a story about the BioMS team, their late-stage clinical trials which are nearing completion, acknowledging the hard work and hope of all involved, revving up energy for the finishing line in 2009 and highlighting the tremendous potential of dirucotide to improve outcomes for MS patients around the world.

Our report presents two stories, running in parallel through the entire annual report. A patient's story and the BioMS story. The cover shows a picture of an older woman's hands tying her granddaughter's ponytail ribbon; the text "Only a few moments in history are as special as this". A simple and powerful message; Finding out if BioMS' drug works – the only drug that could potentially delay progression of MS and thus permit special moments to happen where they might not have. The subsequent pages feature both key moments in the history of BioMS and potential key moments that future patients may be able to experience in spite of MS.

for more information about our annual report services, please contact:

Mike Polonsky (Senior Vice President) 416.815.0700 x231 mpolonsky@equicomgroup.com

Lumir Hladik (Chief Creative Strategist) 416.815.0700 x236 lhladik@equicomgroup.com

Cameron Davies (Vice President, Business Development) 416.815.0700 x260 cdavies@equicomgroup.com